$A

AGILENT TECHNOLOGIES, INC. (A): Results of Operations and Financial Condition

AGILENT TECHNOLOGIES, INC. (A) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Agilent Reports Third-Quarter Fiscal Year 2026 Financial Results Delivers strong Q3 results and raises FY26 revenue growth, margin expansion, and non-GAAP EPS (4) guidance on continued operational momentum Third-quarter fiscal year 2026 • Revenue of $1.88 billion for

Original reporting
Published Aug 26, 2026, 8:06 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 26, 2026, 8:09 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$A
Bullish
high confidence
Mentioned
$A
Relevance
9/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$ABullishHigh
01

Why it matters

The earnings beat and raised guidance are likely to drive immediate buying pressure.

02

Market read

Agilent's strong quarter and upgraded guidance provide a clear catalyst for the stock and its sector.

03

What to watch

Potential supply-chain disruptions or slower adoption of new product lines could temper growth.

Relevance 9/10Novelty 9/10Timing: today
AlphAI · Earnings readA · Third quarter fiscal year 2026 · ended July 31, 2026

Agilent Reports Third-Quarter Fiscal Year 2026 Financial Results Delivers strong Q3 results and raises FY26 revenue growth, margin expansion, and non-GAAP EPS guidance on continued operational momentum

Strong quarter

Revenue grew 8.1% reported and 7.3% core year-over-year, all three operating groups grew, GAAP and non-GAAP operating margins expanded, and management raised fiscal year 2026 revenue growth, non-GAAP operating-margin expansion, and non-GAAP EPS guidance.

Revenue
$1.88 billion
growth of 8.1% reported and up 7.3% core y/y
Life Sciences and Diagnostics Markets Group (LDG)
$746 million
growth of 11% reported and 10% core year-over-year y/y
Operating margin · GAAP
23.6%
expanded by 290 basis points year-over-year y/y · expanded by 190 basis points sequentially q/q
EPS · non-GAAP
$1.62
an increase of 18% from the third quarter of fiscal year 2025 y/y
Fiscal year 2026 and fourth quarter 2026 outlook
Fiscal year 2026: $7.49 billion to $7.51 billion, up 7.8% to 8.1% reported and up 5.8% to 6.0% core. Fourth quarter 2026: $1.98 billion to $2.0 billion, growth of 6.4% to 7.4% reported and up 5.2% to 6.2% core.

Key metrics

as reported
MetricValueq/qy/y
Net revenueGAAP$1.88 billiongrowth of 8.1% reported and up 7.3% core
Net revenueGAAP$1,878 million8%
Cost of products and servicesGAAP$836 million
Research and development expenseGAAP$123 million
Selling, general and administrative expenseGAAP$475 million
Total costs and expensesGAAP$1,434 million
Income from operationsGAAP$444 million
Operating marginGAAP23.6%expanded by 190 basis points sequentiallyexpanded by 290 basis points year-over-year
Non-GAAP income from operationsnon-GAAP$532 million
Non-GAAP operating marginnon-GAAP28.3% (including an approximately 110 basis point net benefit from tariff refunds)expanded by 190 basis points sequentiallyexpanded by 320 basis points year-over-year
Interest incomeGAAP$15 million
Interest expenseGAAP$(29) million
Other income (expense), netGAAP$14 million
Income before taxesGAAP$444 million
Provision for income taxesGAAP$82 million
Net incomeGAAP$362 million
Diluted EPSGAAP$1.28an increase of 8% from the third quarter of fiscal year 2025
Basic EPSGAAP$1.28
Non-GAAP net incomenon-GAAP$459 million (including a $17 million net benefit from tariff refunds)
Non-GAAP diluted EPSnon-GAAP$1.62 (including a $0.06 net benefit from tariff refunds)an increase of 18% from the third quarter of fiscal year 2025
Nine-month net revenueGAAP$5,511 million
Nine-month income from operationsGAAP$1,196 million
Nine-month net incomeGAAP$1,006 million
Nine-month diluted EPSGAAP$3.55
Nine-month non-GAAP net incomenon-GAAP$1,268 million
Nine-month non-GAAP diluted EPSnon-GAAP$4.48
Nine-month net cash provided by operating activitiesGAAP$1,064 million
Nine-month payments to acquire property, plant and equipmentGAAP$(249) million

Segments

SegmentRevenueq/qy/y
Life Sciences and Diagnostics Markets Group (LDG)No segment-specific revenue driver was provided.$746 milliongrowth of 11% reported and 10% core year-over-year
Agilent CrossLab Group (ACG)No segment-specific revenue driver was provided.$786 milliongrowth of 6% reported and 5% core year-over-year
Applied Markets Group (AMG)No segment-specific revenue driver was provided.$346 milliongrowth of 7% reported and 7% core year-over-year

Fiscal year 2026 and fourth quarter 2026 outlook

  • RevenueFiscal year 2026: $7.49 billion to $7.51 billion, up 7.8% to 8.1% reported and up 5.8% to 6.0% core. Fourth quarter 2026: $1.98 billion to $2.0 billion, growth of 6.4% to 7.4% reported and up 5.2% to 6.2% core.
  • NoteFiscal year 2026 non-GAAP operating margin expansion at the midpoint of core revenue growth guidance is expected to be over 130 basis points, including approximately 30 basis points in net benefit from tariff refunds in the third quarter.
  • NoteFiscal year 2026 non-GAAP EPS is expected in the range of $6.18 to $6.21, an increase of 15 cents at the midpoint, including $0.06 net benefit from tariff refunds in the third quarter, versus the prior guide.
  • NoteFourth-quarter 2026 non-GAAP EPS is expected in the range of $1.71 to $1.74 per share.
  • NoteFourth-quarter guidance does not include any future benefit from tariff refunds.
  • NoteFuture amortization of intangibles is expected to be approximately $27 million per quarter.

Capital returns

  • Nine-month payments for repurchase of common stock were $(295) million, compared with $(340) million in the prior-year period.
  • Nine-month payments of dividends were $(216) million, compared with $(212) million in the prior-year period.
  • Nine-month payments of excise taxes related to repurchases of common stock were $(3) million, compared with $(10) million in the prior-year period.

What drove it

  • Company revenue grew 8.1% reported and 7.3% core year-over-year.
  • LDG delivered the fastest reported and core growth, at 11% and 10%, respectively.
  • Management cited improving end markets, stronger demand in key regions, and excellent customer response to innovative product launches.
  • Management attributed operational momentum to its strategy, execution discipline, and the Ignite Operating System.
  • Currency contributed 1 percentage point to company reported revenue growth; core revenue was $1,868 million versus GAAP revenue of $1,878 million.

Concerns

  • Third-quarter GAAP and non-GAAP income from operations each included a $20 million net benefit from tariff refunds, equal to a 110 basis point benefit to GAAP and non-GAAP operating margin.
  • Third-quarter GAAP and non-GAAP net income each included a $17 million net benefit from tariff refunds, and GAAP and non-GAAP EPS each included a $0.06 net benefit.
  • Fourth-quarter guidance does not include any future benefit from tariff refunds.
  • Management identified ongoing competitive, pricing and gross-margin pressures, tariff and trade-policy changes, customer purchasing decisions and timing, and geopolitical uncertainties as risks.
  • Long-term debt was $3,645 million at July 31, 2026, versus $3,050 million at October 31, 2025.

What to watch

  • Fourth-quarter revenue delivery against guidance of $1.98 billion to $2.0 billion and core growth guidance of 5.2% to 6.2%.
  • Fourth-quarter non-GAAP EPS delivery against guidance of $1.71 to $1.74 per share.
  • Whether fiscal year 2026 non-GAAP operating-margin expansion exceeds 130 basis points at the midpoint of core revenue growth guidance.
  • Demand progression in LDG, ACG, and AMG following year-over-year core growth of 10%, 5%, and 7%, respectively.
  • The effect of tariff refunds, as future benefit is excluded from fourth-quarter guidance.
  • Cash generation, acquisition spending, and debt following $950 million of nine-month payments to acquire businesses and intangible assets and $600 million of long-term debt issuance.

Balance sheet and cash flow

  • Cash and cash equivalents were $1,758 million at July 31, 2026, compared with $1,789 million at October 31, 2025.
  • Short-term debt was $304 million at July 31, 2026 and October 31, 2025.
  • Long-term debt was $3,645 million at July 31, 2026, compared with $3,050 million at October 31, 2025.
  • Nine-month net cash provided by operating activities was $1,064 million, compared with $1,014 million in the prior-year period.
  • Nine-month payments to acquire businesses and intangible assets, net of cash acquired, were $(950) million, compared with $4 million in the prior-year period.
  • Nine-month proceeds from issuance of long-term debt were $600 million, compared with $4 million in the prior-year period.
  • Inventory was $1,117 million at July 31, 2026, compared with $1,025 million at October 31, 2025.
  • Accounts receivable, net, was $1,478 million at July 31, 2026, compared with $1,487 million at October 31, 2025.

Analysis

Agilent reported third-quarter revenue of $1.88 billion, up 8.1% reported and 7.3% core from the third quarter of fiscal year 2025. All three operating groups grew. LDG was the largest growth contributor at 11% reported and 10% core growth, while ACG grew 6% reported and 5% core and AMG grew 7% reported and core. Management described improving end markets, stronger demand in key regions, and customer response to product launches.

Profitability expanded materially. GAAP operating margin was 23.6%, up 290 basis points year-over-year and 190 basis points sequentially. Non-GAAP operating margin was 28.3%, up 320 basis points year-over-year and 190 basis points sequentially. The reported margins included a $20 million tariff-refund benefit, equal to approximately 110 basis points. Segment operating margins were 23.5% for LDG, 34.3% for ACG, and 24.9% for AMG.

GAAP net income was $362 million and diluted EPS was $1.28, compared with $336 million and $1.18 in the year-ago quarter. Non-GAAP net income was $459 million and non-GAAP EPS was $1.62, compared with $390 million and $1.37, respectively. The quarter's GAAP and non-GAAP net income included a $17 million tariff-refund benefit, while each EPS measure included a $0.06 benefit. This benefit is important because the company explicitly excludes future tariff-refund benefits from fourth-quarter guidance.

For fiscal year 2026, Agilent raised revenue guidance to $7.49 billion to $7.51 billion, representing 7.8% to 8.1% reported growth and 5.8% to 6.0% core growth. It expects non-GAAP operating-margin expansion of over 130 basis points at the midpoint of core growth guidance and non-GAAP EPS of $6.18 to $6.21. Fourth-quarter guidance calls for $1.98 billion to $2.0 billion of revenue and non-GAAP EPS of $1.71 to $1.74 per share.

Nine-month operating cash flow was $1,064 million, while payments to acquire businesses and intangible assets were $950 million. Agilent also repurchased $295 million of common stock and paid $216 million of dividends over the nine-month period. Cash and cash equivalents were $1,758 million at July 31, 2026, and long-term debt was $3,645 million, compared with $3,050 million at October 31, 2025.

Management, verbatim

Agilent’s exceptional third-quarter performance reflects the sustained momentum created by our strategy, our execution discipline, and the compounding impact of the Ignite Operating System. We are seeing improving end markets, stronger demand in key regions, and excellent customer response to our innovative product launches. All of this gives us confidence in our increased outlook and our ability to sustainably outperform our end markets.

Padraig McDonnell, CEO

Not in the filing

stated, not guessed
  • Previous-quarter outlook figures were not provided, so comparisons of actual results with prior guidance cannot be completed.
  • Consolidated gross margin was not reported.
  • Quarterly operating cash flow was not reported; only nine-month operating cash flow was reported.
  • Free cash flow was not reported.
  • Gross-margin guidance was not reported.
  • Operating-expense guidance was not reported.
  • Tax-rate guidance was not reported.
  • Prior-quarter revenue, net income, EPS, and segment revenue figures were not reported.

AlphAI analysis generated from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was cross-checked against the filing text; consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Background

The filing is Agilent's first public disclosure of Q3 results and FY2026 outlook.

Company-level read

Ticker impact

$ABullishHigh confidence
Context

Agilent Technologies reported Q3 FY2026 results and raised FY2026 revenue and EPS guidance.

Expected impact

Potential short-term rally as investors price in higher revenue and EPS outlook.

Evidence & confidence

Revenue grew 8.1% YoY, operating margins expanded, and guidance was lifted, all indicating improved fundamentals.

Market effects

Life sciences and diagnostics equipment sector may see broader optimism from Agilent's beat.

North American lab equipment market could benefit from higher demand signals.

Agilent's global footprint means the guidance lift may influence worldwide analytical instrument suppliers.

Counterpoint

If margin expansion stalls or tariff refund benefits fade, the stock could face downside.

Key entities

  • Padraig McDonnell

    CEO of Agilent Technologies who commented on the results.

Every A earnings report

This story covers one filing. The ticker page keeps them all: each quarter's reported metrics with year-over-year and sequential comparisons, segments, guidance, and how the numbers landed against the company's own prior outlook.

Related articles

$AMed

Agilent (A) Upgraded to Buy: What Does It Mean for the Stock?

Agilent Technologies (A) has been upgraded to a Zacks Rank #2 (Buy), reflecting an upward trend in earnings estimates. The Zacks rating system, which is based on earnings estimate revisions, suggests a positive outlook for the company's stock price. Analysts have raised their estimates for Agilent by 3.4% over the past three months, with the company expected to earn $6.17 per share for the fiscal year ending October 2026.

$AHighAI 8/10

Agilent (A) Q3 2026 Earnings Call Transcript

Agilent (A) reported Q3 2026 revenue of $1.88B, up 7.3% and exceeding guidance. EPS was $1.56, up 14% YoY. Strong performance driven by pharma, China growth, and Ignite strategy. Key growth areas include pharma, semiconductors, and AI infrastructure.

$AHighAI 8/10

Stronger Q3 Results and Raised Guidance Could Be A Game Changer For Agilent Technologies (A)

Agilent Technologies (A) reported Q3 2026 sales of $1.88B and net income of $362M, with EPS rising to $1.28. The company raised its full-year revenue and profit guidance, citing strong demand in pharma, China, and advanced materials, plus cost savings from its Ignite program. The updated outlook suggests margin benefits and product launches are offsetting cost pressures. Investors should note ongoing tariff and supply chain risks. Analysts' fair value estimates for Agilent range from $150.54 to

$AHighAI 8/10

Agilent earnings analysis: questions answered and next catalysts

Agilent reported FY2026 Q3 earnings with EPS of $1.62 (8.7% above consensus) and revenue of $1.88B (2.2% above estimates). This marks the third consecutive quarter of EPS acceleration, with revenue growth of 6.7% in FY2025. However, gross margins slipped to 52.4% and free cash flow declined to $1.15B. The stock trades at 30.9x trailing P/E, with a fair-value estimate of $145.64, suggesting a 7.6% overvaluation.